MedPath

The influence of modafinil on the post-exercise exacerbation of symptoms in patients with chronic fatigue syndrome

Phase 3
Recruiting
Conditions
chronic fatigue syndrome
Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
Registration Number
ACTRN12616000487415
Lead Sponsor
niversity of New South Wales
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

i) meeting international diagnostic criteria for chronic fatigue syndrome (Fukuda, 1994)
ii) have their treating exercise physiologist and clinical psychologist resolve that they have a stable pattern of symptom severity, as well as having optimized and stable sleep patterns and well-managed mood disturbance
iii) undertaking regular of 10-20 minutes walking at a gentle pace without producing a post-exertional exacerbation of symptoms (that is an hour or more of worsened fatigue and other symptoms).

Exclusion Criteria

i) currently use beta-blockers or other agents known to affect heart rate response to exercise; or
ii) have any medical (e.g. lower limb injury) condition which may preclude reliable participation in exercise testing
iii) currently use central nervous system medications (e.g. Benzodiazepines and other sedative-hyponotics (e.g. stilnox), anti-epileptics, high-dose antidepressants (low-dose allowed),
iv) are pregnant or breastfeeding
v) have hepatic impairment
vi) are hypersensitive to modafinil
vii) have a history of left ventricular hypertrophy or ischaemic heart disease, or other clinically significant cardiac disease;
viii) uncontrolled anxiety disorder,
ix) have previously taken modafinil and experienced an adverse reaction.
x) taking anti-hypertensives/beta blockers
xi) taking corticosteroids
xii) taking major analgesics (e.g. oxycodone)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath